NO332182B1 - 2-alkynyl- og 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidin-adenosin A2a-reseptorantagonist, anvendelse derav for fremstilling av et medikament, og farmasoytisk preparat omfattende forbindelsen - Google Patents

2-alkynyl- og 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidin-adenosin A2a-reseptorantagonist, anvendelse derav for fremstilling av et medikament, og farmasoytisk preparat omfattende forbindelsen Download PDF

Info

Publication number
NO332182B1
NO332182B1 NO20055510A NO20055510A NO332182B1 NO 332182 B1 NO332182 B1 NO 332182B1 NO 20055510 A NO20055510 A NO 20055510A NO 20055510 A NO20055510 A NO 20055510A NO 332182 B1 NO332182 B1 NO 332182B1
Authority
NO
Norway
Prior art keywords
alkyl
mmol
preparation
mixture
product
Prior art date
Application number
NO20055510A
Other languages
English (en)
Norwegian (no)
Other versions
NO20055510L (no
NO20055510D0 (no
Inventor
Bernard R Neustadt
Samuel Chackalamannil
Andrew W Stamford
Craig D Boyle
Jinsong Hao
Hong Liu
Unmesh G Shah
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20055510D0 publication Critical patent/NO20055510D0/no
Publication of NO20055510L publication Critical patent/NO20055510L/no
Publication of NO332182B1 publication Critical patent/NO332182B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20055510A 2003-04-23 2005-11-22 2-alkynyl- og 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidin-adenosin A2a-reseptorantagonist, anvendelse derav for fremstilling av et medikament, og farmasoytisk preparat omfattende forbindelsen NO332182B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46484003P 2003-04-23 2003-04-23
PCT/US2004/012471 WO2004094431A2 (en) 2003-04-23 2004-04-21 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine a2a receptor antagonists

Publications (3)

Publication Number Publication Date
NO20055510D0 NO20055510D0 (no) 2005-11-22
NO20055510L NO20055510L (no) 2006-01-20
NO332182B1 true NO332182B1 (no) 2012-07-23

Family

ID=33310963

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055510A NO332182B1 (no) 2003-04-23 2005-11-22 2-alkynyl- og 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidin-adenosin A2a-reseptorantagonist, anvendelse derav for fremstilling av et medikament, og farmasoytisk preparat omfattende forbindelsen

Country Status (32)

Country Link
US (2) US6897217B2 (de)
EP (1) EP1622912B1 (de)
JP (2) JP4527712B2 (de)
KR (1) KR100831107B1 (de)
CN (1) CN100503609C (de)
AR (1) AR044041A1 (de)
AT (1) ATE432282T1 (de)
AU (1) AU2004233334B2 (de)
BR (1) BRPI0409787B8 (de)
CA (1) CA2522813C (de)
CL (1) CL2004000847A1 (de)
CO (1) CO5700766A2 (de)
CY (1) CY1109263T1 (de)
DE (1) DE602004021250D1 (de)
DK (1) DK1622912T3 (de)
EC (1) ECSP056115A (de)
ES (1) ES2326270T3 (de)
HK (1) HK1085466A1 (de)
HR (1) HRP20090394T1 (de)
IL (1) IL171567A (de)
MX (1) MXPA05011366A (de)
MY (1) MY139344A (de)
NO (1) NO332182B1 (de)
NZ (1) NZ542823A (de)
PE (1) PE20050141A1 (de)
PL (2) PL1622912T3 (de)
PT (1) PT1622912E (de)
RU (1) RU2373210C2 (de)
SI (1) SI1622912T1 (de)
TW (2) TWI355381B (de)
WO (1) WO2004094431A2 (de)
ZA (1) ZA200508489B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7313588B1 (en) * 2000-07-13 2007-12-25 Biap Systems, Inc. Locally executing software agent for retrieving remote content and method for creation and use of the agent
WO2003048165A1 (en) * 2001-11-30 2003-06-12 Schering Corporation ADENOSINE A2a RECEPTOR ANTAGONISTS
US20060128694A1 (en) * 2002-12-19 2006-06-15 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
JP2006514697A (ja) 2002-12-19 2006-05-11 シェーリング コーポレイション アデノシンA2aレセプターアンタゴニストの使用
CN100503609C (zh) * 2003-04-23 2009-06-24 先灵公司 2-炔基-及2-链烯基-吡唑并-[4,3-e]-1,2,4-三唑并[1,5-c]-嘧啶腺苷A2a受体拮抗剂
WO2005103055A1 (en) * 2004-04-21 2005-11-03 Schering Corporation PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PYRIMIDINE ADENOSINE A2A RECEPTOR ANTAGONISTS
ATE556712T1 (de) * 2005-06-07 2012-05-15 Kyowa Hakko Kirin Co Ltd A2a antagonisten zur behandlung von motorischen störungen
WO2007035542A1 (en) 2005-09-19 2007-03-29 Schering Corporation 2-HETEROARYL-PYRAZOLO-[4, 3-e]-1, 2, 4-TRIAZOLO-[1,5-c]-PYRIMIDINE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
AR056080A1 (es) * 2005-09-23 2007-09-19 Schering Corp 7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
US7691869B2 (en) 2007-03-30 2010-04-06 King Pharmaceuticals Research And Development, Inc. Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity
WO2009111449A1 (en) * 2008-03-04 2009-09-11 Schering Corporation 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e] -1,2,4-triazolo [4,3-c] pyrimidin-3-one compounds for use as adenosine a2a receptor antagonists
US8512594B2 (en) * 2008-08-25 2013-08-20 Air Products And Chemicals, Inc. Curing agent of N,N′-dimethyl-meta-xylylenediamine and multifunctional amin(s)
US8501997B2 (en) * 2008-08-25 2013-08-06 Air Products And Chemicals, Inc. Curing agent for low temperature cure applications
ES2487616T3 (es) 2009-03-10 2014-08-22 Takeda Pharmaceutical Company Limited Derivados de benzofurano
EP2462144B1 (de) * 2009-08-07 2017-09-20 Merck Sharp & Dohme Corp. Verfahren zur herstellung eines 2-alkinyl substituierten 5-amino-pyrazolo-[4, 3-e]-1,2,4-triazolo [1,5-c] pyrimidins
US8420661B2 (en) * 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
KR20140113918A (ko) * 2011-12-27 2014-09-25 (주)바이오팜솔루션즈 루게릭병의 치료 또는 예방에 사용되는 페닐카바메이트 화합물
WO2014101120A1 (en) * 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
ES2824723T3 (es) * 2013-03-14 2021-05-13 Galapagos Nv Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de trastornos inflamatorios
EP3723754A4 (de) 2017-12-13 2021-05-19 Merck Sharp & Dohme Corp. Imidazo[1,2-c]chinazolin-5-amin-verbindungen mit eigenschaften von a2a-antagonist
JP2022540583A (ja) * 2019-07-17 2022-09-16 テオン セラピューティクス,インク. アデノシンa2a受容体アンタゴニスト及びその使用
CN115160120B (zh) * 2022-08-02 2024-08-27 乐威医药(江苏)股份有限公司 一种多烷氧基芳香酮的合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US785906A (en) * 1904-12-06 1905-03-28 Albert P Mcbride Casing packer and shoe for gas or oil wells.
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
ATE208199T1 (de) * 1993-07-27 2001-11-15 Kyowa Hakko Kogyo Kk Arzneimittel gegen parkinsonsche krankheit
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
DE19826843A1 (de) * 1998-06-16 1999-12-23 Boehringer Ingelheim Pharma Neue Imidazotriazolopyrimidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
SK287748B6 (sk) * 2000-05-26 2011-08-04 Schering Corporation Substituované 5-amino-pyrazolo[4,3-e]-1,2,4-triazolo[1,5- c]pyrimidíny, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
GB0100624D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
CA2437437A1 (en) * 2001-02-05 2002-08-15 Yasuhisa Kurogi Triazoloquinazoline and pyrazolotriazolopyrimidine derivatives, pharmaceutical, composition adenosine a3 receptor affinitive agent, intraocular-pressure reducing agent, pharmaceutical preparation for prevention and treatment of glaucoma, and intraocular-pressure reducing method
PE20030477A1 (es) 2001-10-15 2003-06-06 Schering Corp ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a
JP2006514697A (ja) 2002-12-19 2006-05-11 シェーリング コーポレイション アデノシンA2aレセプターアンタゴニストの使用
CN100503609C (zh) * 2003-04-23 2009-06-24 先灵公司 2-炔基-及2-链烯基-吡唑并-[4,3-e]-1,2,4-三唑并[1,5-c]-嘧啶腺苷A2a受体拮抗剂

Also Published As

Publication number Publication date
BRPI0409787A (pt) 2006-05-30
AU2004233334B2 (en) 2010-08-12
US20040220194A1 (en) 2004-11-04
TW200427689A (en) 2004-12-16
PL378867A1 (pl) 2006-05-29
MY139344A (en) 2009-09-30
ECSP056115A (es) 2006-03-01
ATE432282T1 (de) 2009-06-15
CL2004000847A1 (es) 2005-03-11
AR044041A1 (es) 2005-08-24
DK1622912T3 (da) 2009-09-07
PE20050141A1 (es) 2005-04-01
NO20055510L (no) 2006-01-20
TWI355381B (en) 2012-01-01
WO2004094431A3 (en) 2004-12-02
PT1622912E (pt) 2009-08-17
CN100503609C (zh) 2009-06-24
ES2326270T3 (es) 2009-10-06
WO2004094431A2 (en) 2004-11-04
US6897217B2 (en) 2005-05-24
HRP20090394T1 (en) 2009-08-31
CY1109263T1 (el) 2014-07-02
AU2004233334A1 (en) 2004-11-04
KR20060005379A (ko) 2006-01-17
DE602004021250D1 (de) 2009-07-09
JP2010059178A (ja) 2010-03-18
TWI375677B (en) 2012-11-01
BRPI0409787B8 (pt) 2021-05-25
JP4527712B2 (ja) 2010-08-18
BRPI0409787B1 (pt) 2018-08-21
NZ542823A (en) 2009-03-31
KR100831107B1 (ko) 2008-05-20
RU2005136166A (ru) 2006-06-10
PL1622912T3 (pl) 2009-11-30
CA2522813A1 (en) 2004-11-04
SI1622912T1 (sl) 2009-10-31
US7368449B2 (en) 2008-05-06
CO5700766A2 (es) 2006-11-30
TW201144317A (en) 2011-12-16
CN1777609A (zh) 2006-05-24
JP2006523619A (ja) 2006-10-19
CA2522813C (en) 2009-09-08
NO20055510D0 (no) 2005-11-22
HK1085466A1 (en) 2006-08-25
RU2373210C2 (ru) 2009-11-20
EP1622912A2 (de) 2006-02-08
ZA200508489B (en) 2007-04-25
US20050222164A1 (en) 2005-10-06
EP1622912B1 (de) 2009-05-27
MXPA05011366A (es) 2005-11-28
IL171567A (en) 2013-01-31

Similar Documents

Publication Publication Date Title
NO332182B1 (no) 2-alkynyl- og 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidin-adenosin A2a-reseptorantagonist, anvendelse derav for fremstilling av et medikament, og farmasoytisk preparat omfattende forbindelsen
US11279713B2 (en) Heterocyclic compound and use thereof
JP4938348B2 (ja) アデノシンa2aレセプターアンタゴニスト
US7709492B2 (en) Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
US9527807B2 (en) Sulfonamide derivative and use thereof
JP4429724B2 (ja) [1,2,4]−トリアゾール二環式アデノシンA2aレセプタアンタゴニスト
NZ561414A (en) Method and composition for treating peripheral vascular diseases
JP2007507533A (ja) 肥満および関連障害の処置のための、選択的メラニン凝集ホルモンレセプターアンタゴニストとしてのアミノベンズイミダゾール
EP1706375A2 (de) Substituierte n-aryl-amidine als selektive d1-dopaminrezeptorantagonisten zur behandlung von obesitas und cns-erkrankungen
CZ2000947A3 (cs) Substituované chromanové deriváty

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MERCK SHARP AND DOHME CORP

Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY, US

MM1K Lapsed by not paying the annual fees